What is Brief History of Reckitt Benckiser Group Company?

After the Reckitt and Benckiser merger, management prioritized Powerbrands such as Finish, Vanish, Calgon, and Veet, directing outsized investment into marketing and distribution and expanding strongly into North America, Asia and LATAM; Dettol scaled across India and MENA. In 2005 Reckitt acquired Boots Healthcare International for £1.93 billion, adding Nurofen, Strepsils and Clearasil and marking a decisive entry into OTC consumer health.

New product cadence accelerated with launches like Finish Quantum, Vanish Oxi Action and Veet waxing strips supported by higher media and in-store activation. The 2012 acquisition of U.S. rights to Mucinex (Schiff/Adams Respiratory) strengthened cough‑cold presence while divestments of non‑core foods culminated in the 2012 sale of remaining North American private‑label food assets, sharpening focus on health and hygiene.

Reckitt exited prescription pharmaceuticals in 2014 by spinning off Indivior, lowering regulatory exposure. In 2017 the company acquired Mead Johnson Nutrition for an enterprise value of $17.9 billion, adding Enfamil and Nutramigen and creating a Nutrition pillar that materially increased exposure to high‑growth Asian markets while adding integration and supply chain complexity.

Reckitt re-segmented into Health, Hygiene and Nutrition. COVID‑19 drove double‑digit growth for disinfectant brands such as Lysol and Dettol; Lysol secured EPA approvals for SARS‑CoV‑2 claims in 2020. The group invested in production capacity and commercial partnerships (for example with major travel and hospitality partners) and continued portfolio pruning, selling Scholl in 2021 and later divesting E45.

Following U.S. infant formula disruptions, Enfamil gained share as the group focused on supply resilience and brand equity. By FY2024 group net revenue was approximately £14.6–£14.8 billion with adjusted operating margin in the mid‑20% range, driven by price/mix and productivity programs. Leadership maintained disciplined A&P around 12–13% of sales and targeted ongoing productivity savings in excess of £200m per year.

The period illustrates RB Group origins and the evolution of its product portfolio through major acquisitions and divestments, accelerated innovation, and geographic expansion—core elements in the Reckitt Benckiser history and company profile. Read more on strategy and values at Mission, Vision & Core Values of Reckitt Benckiser Group.

Reckitt is prioritising germ protection, auto-dish premium tablets, OTC self-care, sexual wellness and specialty infant formula, leveraging science-backed claims and digital retail media to drive share gains.

Management targets steady mid-single-digit like-for-like revenue growth and margin expansion via productivity, mix improvements and disciplined capital allocation.

Strategic initiatives include supply-chain redundancy for infant nutrition, productivity programmes delivering >£200m pa savings, and e-commerce and RGM disciplines to protect margins.

Expansion focuses on India, China and Southeast Asia, sharpening the portfolio around scale brands with #1/#2 positions to exploit ageing populations, self-care trends and hygiene normalisation.